RadNet, Inc. Third Quarter 2026 Financial Results Conference Call - RADNET INC

Financial Performance:

• Total company revenue reached a record $683 million (adjusted to $638.3 million in specific breakdown context, with 22.1% YoY growth) in Q3 2026.
• Adjusted EBITDA hit a record $105 million (up 23.8% YoY), driving an adjusted EBITDA margin expansion of 230 basis points to 16.5%.
• Imaging center segment adjusted EBITDA rose 25.3% to $102 million with a margin expansion of 511 basis points; procedural volumes increased 19.9% aggregate and 8.9% same-center.
• Digital health revenue grew 33% to $32.9 million; segment adjusted EBITDA was $3 million with margins expanding to 9.1% despite integration costs.
• Liquidity remains strong with $750.6 million in cash and a net debt-to-adjusted EBITDA leverage ratio of 1.66x; Day Sales Outstanding (DSO) maintained at 31 days.
• Diluted adjusted earnings per share were $0.30 compared to $0.24 in the prior year period.

Guidance and Future Outlook:

• Raised full-year 2026 imaging center revenue guidance to $2.385 billion–$2.435 billion; adjusted EBITDA guidance raised to $350 million–$363 million.
• 2026 Imaging Center free cash flow guidance increased to $120 million–$130 million; capital expenditure guidance raised to $170 million–$180 million.
• Digital health segment 2026 adjusted EBITDA guidance raised to $11 million–$13 million (before non-capitalized R&D); revenue guidance reaffirmed at $135 million–$145 million.
• Management projects Q4 digital health ARR to exceed $140 million, with a sequential revenue growth of ~20% driven by new go-lives and contract values.
• 2027 outlook anticipates continued volume growth in advanced imaging, integration benefits from OnRad, and revenue conversion from $140M+ ARR base.

Business Segments and Product Lines:

• Imaging Centers: Advanced imaging mix (MRI, CT, PET-CT) increased to 30.6% of total volume; 37% of centers (161 of 439) are held in health system joint ventures.
• OnRad Acquisition: Pending acquisition of OnRad expected to add $190M–$200M revenue and $60M–$65M EBITDA in Year 1; will form the "Radiology Professional Services" segment.
• Digital Health: Annual Recurring Revenue (ARR) reached $112.6 million (up 67% YoY), with external ARR now comprising 65% of the base ($73 million); pipeline of total contract value grew to over $300 million.
• Product launches: Received FDA clearance for breast arterial calcification assessment, breast ultrasound, and next-gen chest X-ray (built on proprietary foundation model); portfolio now holds 28 FDA clearances and 26 CE marks.
• Internal Deployment: 30% of RadNet exams covered by AI-powered Reporting Pro; goal to reach >50% imaging volume report automation by Q3 2027.

Market and Competitive Landscape:

• Advanced Imaging Trends: Demand accelerating due to aging population and new AI-driven equipment speeds (e.g., PET-CT scans reduced from 1 hour to <15 minutes).
• Health System Partnerships: Growing pressure on hospital outpatient departments due to site neutrality provisions; driving increased interest in joint ventures and outsourcing to freestanding centers.
• Professional Services Gap: Shortage of trained radiologists creating supply/demand imbalance, increasing reliance on teleradiology and staffing solutions like OnRad.
• Competitive Advantage: RadNet differentiates via end-to-end AI suite, FDA-cleared tools, and "land and shift" strategy to integrate hospital radiology departments.

Risks and Challenges:

• Medicare Reimbursement: Final 2027 CMS rule projects a ~$5 million revenue impact due to a 2.3% decrease in the conversion factor; potential legislative reversal in December remains uncertain.
• Labor Market: Ongoing shortages of radiologists and technologists driving salary pressure, though mitigated by remote tech solutions (TechLive) and AI automation.
• Integration Risks: Temporary margin dilution from acquisitions (Gleamer) and investment in commercial/implementation headcount for Digital Health.
• Regulatory Compliance: Need to maintain FDA clearance and ensure AI tools do not "hallucinate," requiring continuous monitoring and accuracy verification.

Management Commentary and Tone:

• Confidence Level: Management expressed high confidence in record Q3 performance and a strong Q4 outlook, describing the quarter as "broad-based" and "robust."
• Strategic Vision: CEO Dr. Berger emphasized a shift from diagnosis/treatment to early prevention via AI, positioning RadNet as a long-term leader in transforming radiology workflows.
• Operational Focus: Strong emphasis on "land and shift" for hospital integrations, utilizing OnRad to bring outpatient efficiencies and AI tools into hospital settings.
• Investment Stance: Willing to maintain high CapEx to replace aging hardware with high-speed tech and open new de novo centers (10 planned for 2026 vs. 7 previously).

Analyst Questions and Answers:

• Q: Advanced Imaging Growth Drivers? A: Driven by aging population, new technology (faster PET/CT), and specific procedural shifts like coronary CT angiography and high-risk breast MRI screening.
• Q: Digital Health Revenue Visibility? A: Q4 revenue expected >$40 million, supported by $140M ARR run-rate, existing backlog, RedNet internal deployments, and new perpetual licenses.
• Q: OnRad EBITDA Target? A: Deal includes a 2027 EBITDA earn-out trigger of $56 million; for every dollar above, a 15x multiple payout in cash or stock.
• Q: Capacity Expansion Metrics? A: Growth driven by extended hours, new hardware efficiency, digital registration tools (75% potential front-desk elimination), and aggressive de novo site openings.
• Q: AI Productivity Impact? A: Goal is 50-60% report automation by Q2 2027; benefits realized primarily in radiologist cost avoidance and faster turnaround times rather than immediate gross margin expansion.
• Q: Gleamer Customer Acquisition? A: 63 new customers added in Q3, all net-new externally (minimal overlap with existing RadNet); significant cross-sell potential into the broader Deep Health portfolio.

Other Key Points:

• Digital Registration Tool: Pilot at ~30 centers shows 1/3 of registrations fully digital without front-desk interaction; full rollout expected by Q1/Q2 2027.
• TechLive Remote Operations: Currently covering 13% of MRI scans with remote technologists; expanding to train techs to control multiple machines simultaneously.
• RSNA Showcase: Management plans to unveil the full Deep Health portfolio at the RSNA conference in Chicago.
• CapEx Strategy: High capital investment is viewed as "growth CapEx" due to the replacement of old scanners with high-throughput, AI-integrated equipment.
• Reimbursement Codes: Thyroid and breast ultrasound AI solutions utilizing existing Category 3 CPT codes for quantitative tissue characterization.